Board summary
Key figures
53,505
Registered population
61.3% aged 18–64
18.5%
Aged 65+
ICB 14.9% · England 17.9%
30.3%
In IMD quintile 1
ICB 40.7% · England 21.0%
~19,466
Core20 residents (est.)
Resident basis; registered basis ~16,533 · see page 3
9,082
Hypertension register
+5.45% in 3 yrs · England +5.60%
470
SMI register
20% of Tameside (LAD)'s
1,546
COPD register
Reviews +4.19% in 3 yrs
Forecast to 2030
10,424
Hypertension patients, 2030
+1,342 on today
74.9%
QRISK ≥20% on statins, 2030
+1.64pp over 3 yrs
4.9%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Annual asthma reviews lag and are falling.
Coverage is below England (65.7%) after a -5.4% 2023 to 2025 change (England +4.4%), leaving a scale indicator of 1,468 unreviewed patients.
Under-80s hypertension blood pressure control trails.
Control is below England (67.8%) with a -0.1% 2023 to 2025 change (England +3.2%) and 64.7% overall treated to target, suggesting titration audit.
SMI checks and lipid therapy exceed England.
Annual SMI blood pressure checks beat England (83.4%) after rising +8.4 pp over 2023 to 2025, alongside 71.5% QRISK lipid therapy (England 63.6%).
Population, age and ethnicity
Older adults comprise 18.5% of registered patients, exceeding borough and ICB comparators
Across 53,505 registered patients, Denton PCN has an older age profile: 18.5% (9,877 patients) are aged 65+, above Tameside (LAD) (16.4%), NHS Greater Manchester Integrated Care Board (14.9%) and England (17.9%). Children aged 0-17 represent 20.3% (10,852 patients), below Tameside (LAD) (21.3%) and NHS Greater Manchester Integrated Care Board (21.8%) but above England (19.6%). Census estimates record 0.1% Gypsy or Irish Traveller and 0.1% Roma residents. Projected list growth to 2030 is 1.6% (methodology unverified; Tameside (LAD) 1.4%, England 2.3%).
Age profile
65+: ICB 14.9%, England 17.9%
Older people · falls rows are Tameside (LAD) local-authority (LA) data, not PCN
| Measure | Local | North West | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Tameside LA) | 2,047 | 2,071 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 83.8% | 82.9% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 56.0% | 56.6% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Tameside LA) | 1,045 | 1,021 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Tameside LA) | 32.5 | 18.2 | 14.8 | 2022‑24 |
Deprivation and Core20
Core20 deprivation averages 30.3% across the PCN but spans 39.3 percentage points between practices
Core20 registered share is 30.3%, above England (21.0%) but below Tameside (LAD) (40.9%) and NHS Greater Manchester Integrated Care Board (40.7%). Weighted practice share is 30.9% (a 0.63 pp reconciliation difference), while estimated resident Core20 counts 19,466. Practice concentration spans 39.3 pp, led by Denton Medical Practice (50.7%) and Guide Bridge Medical Practice (49.0%), down to Medlock Vale Medical Practice (11.4%). By volume, Millgate Healthcare Partnership holds 7,517 estimated Core20 patients (36.2% share). Resource allocation could balance high-share outreach against high-volume list capacity.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
470
SMI register
0.88% recorded prevalence
367
Learning disability register
0.69% recorded prevalence
10
Care homes, 313 beds
In the PCN catchment
9.7%
Provide unpaid care
Tameside (LAD), Census 2021
Learning disability prevalence is 0.7% (367 patients; Tameside (LAD) 0.7%, England 0.6%) and severe mental illness is 0.9% (470 patients; Tameside (LAD) 1.0%, England 1.0%). Catchment sites include 10 care homes with 313 beds.
Severe mental illness: physical health checks
Recorded SMI blood pressure checks reach 88.5% (England 83.4%) and BMI checks reach 87.0% (England 82.1%). Psychosis alcohol recording is 88.2% (England 81.8%). While recorded individual elements exceed national benchmarks, uncaptured components mean full health check bundles cannot be assumed.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
9,082
Hypertension register
+5.45%
Register growth, 3 yrs
Tameside (LAD) +5.50% · England +5.60%
−0.04pp
BP control, under 80
≤140/90 · +4.20pp aged 80+
+1,342
More patients by 2030
Forecast 10,424 (18.86%)
Hypertension case-finding and control
Hypertension recorded prevalence is 17.0% (9,082 patients), above England (15.2%) and NHS Greater Manchester Integrated Care Board (14.4%) but below Tameside (LAD) (17.4%), giving an unadjusted benchmark register gap range of -933 to +219 patients. Recent blood pressure readings reach 87.1% (England 90.0%; Tameside (LAD) 89.2%; ICB 90.3%). Overall treated to target is 64.7% (England 70.3%; ICB 71.4%), while under-80s blood pressure control is 60.3% (England 67.8%; Tameside (LAD) 65.2%; ICB 68.6%), falling 0.1% over 2023 to 2025 (England +3.2%). Crude prevalence does not establish undiagnosed disease, and denominators include personalised care adjustments. Blood pressure control lags national benchmarks, showing a clinical priority to focus on treatment titration and structured recall.
Lipids and statins
Lipid-lowering therapy for QRISK ≥ 20% is 71.5% (Tameside (LAD) 69.2%; ICB 67.0%; England 63.6%), while chronic kidney disease coverage is 82.9% (Tameside (LAD) 78.2%; ICB 73.6%; England 70.3%). Denominators include personalised care adjustments. Therapy coverage exceeds all benchmarks, showing strong primary and secondary prevention prescribing that practices should sustain.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 118,782 | £2.00 | £1.94 | £1.86 | £237,564 |
| Cardiovascular (all), 2025 | 167,894 | £2.63 | £3.15 | £3.33 | £441,561 |
In 2026, Denton PCN prescribed 118,782 lipid-regulating items (£237,564 spend) at £2.00 per item (Tameside (LAD) £2.01; ICB £1.94; England £1.86). The PCN spends £16,629 more than at England's unit cost across 118,782 items, though unit cost does not indicate efficiency. Higher unit costs than England suggest an operational opportunity to review formulary choices and product mix.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
−5.36%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
−4.26%
Asthma prevalence, PCN 3-yr % change
Asthma prescribing in 5-19s is 2,269 items per 1,000 (England 1,488; Tameside (LAD) 2,233). Annual asthma reviews stand at 57.7% (England 65.7%), falling 5.4% over 2023 to 2025 (England +4.4%), leaving a scale indicator of 1,468 unreviewed patients across the 3,469 register. COPD prevalence is 2.9% (England 1.9%), but reviews lag at 69.5% (England 76.4%). High prescribing alongside trailing reviews may reflect review or preventative shortfalls, not verified locally.
Cancer register and children's immunisation
The cancer register records 2,138 patients (4.0% prevalence; England 3.8%). In childhood immunisations, 6-in-1 coverage at 12 months is 92.9% (England 91.0%), but MMR1 at 24 months trails at 84.7% (England 88.3%). By age 5, MMR1 reaches 93.5% but MMR2 drops to 83.1% (a 10.4 pp difference), while the 4-in-1 booster is 78.2% (England 80.9%), below the 95.0% standard by 16.8 pp.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
55.6%
Greater Manchester ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~2,270
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Greater Manchester ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Lung | 40.4% | 33.8% | 15% | 2,193 |
| Prostate | 61.7% | 53.2% | 14% | 1,788 |
| Breast | 82.5% | 85.4% | 19% | 1,758 |
| Bowel | 46.3% | 47.0% | 19% | 1,427 |
| Skin cancer | 84.5% | 87.8% | 27% | 580 |
In 2022, across NHS Greater Manchester ICB, 55.6% of cancers with a known stage (6,491 of 11,679) were diagnosed early (stage 1 or 2), against 55.3% in England. This sits 19.4 pp below the 75.0% national ambition by 2028, representing about 2,270 extra early cases across the ICB. Stage was known for 70.8% of 16,492 cancers. System staging does not reflect PCN performance. Within Denton PCN, cervical screening in women aged 25 to 49 is 68.3% (England 66.8%), but fell 1.7% over 2023 to 2025 (England -1.0%), dropping to 59.7% at Market Street Medical Practice.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In Jul 2026 (provisional), Tameside and Glossop Integrated Care NHS Foundation Trust achieved 76.8% on the cancer 62-day referral to treatment standard (distance of -8.2 pp to the 85.0% standard), above Stockport NHS Foundation Trust (74.7%), Manchester University NHS Foundation Trust (72.8%), NHS Greater Manchester Integrated Care Board (75.7%) and England (71.2%). On the 28-day faster diagnosis standard, the trust reached 82.5% against the 75.0% standard (Stockport 83.2%, Manchester University 80.1%, ICB 79.5%, England 79.3%). For Jul 2026 diagnostic waits of 6+ weeks, the trust recorded 0.0% for MRI and 0.2% for CT (England 21.4% and 9.9%).
| Pathways within standard (%) | Tameside and Glossop Integrated Care | Manchester | Stockport | Greater Manchester ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 82.48 | 80.06 | 83.21 | 79.53 | 79.32 |
| 31-day treatment (96%) | 96.25 | 92.54 | 97.39 | 96.49 | 92.50 |
| 62-day referral to treatment (85%) | 76.77 | 72.85 | 74.67 | 75.73 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Tameside and Glossop Integrated Care | Manchester | Stockport | England |
|---|---|---|---|---|
| MRI | 0.00 | 11.68 | 1.41 | 21.40 |
| CT | 0.18 | 14.66 | 2.93 | 9.92 |
| Echocardiography | 0.00 | 4.91 | 17.46 | 28.48 |
| Colonoscopy | 1.51 | 4.51 | 5.53 | 30.83 |
| Gastroscopy | 5.45 | 29.35 | 5.31 | 29.02 |
| All 15 DM01 tests | 0.80 | 8.98 | 14.08 | 23.14 |
| Community services activity | Tameside residents | Greater Manchester ICB |
|---|---|---|
| Care contacts | 50,685 | 573,310 |
| Referrals | 9,450 | 94,470 |
| Patients with a contact | 15,790 | 183,535 |
Community services (residents of Tameside), Jun 2026 (provisional). In Jun 2026 (provisional), adults aged 65+ accounted for 52.1% of community service contacts among Tameside residents (26,410 of 50,685 total contacts). These dataset figures reflect borough-wide resident activity rather than PCN-specific delivery, illustrating substantial community health service use by older populations across the borough.
Practice variation and patient experience
Practice variation and patient experience
In 2025/26, QOF overall achievement was 88.9% at Guide Bridge Medical Practice and 100.0% at Market Street Medical Practice (England 92.5%). QOF clinical-domain achievement was 97.4% at Denton Medical Practice (England 97.1%). QOF vaccination and immunisation-domain achievement was 15.6% at Guide Bridge Medical Practice and 100.0% at Market Street Medical Practice (England 55.2%).
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Market Street | 109 | 12.8 | 65.8% | 77.8% | 82.8% |
| Medlock Vale | 101 | 11.4 | 61.0% | 76.7% | 80.8% |
| Droylsden Medical | 102 | 14.8 | 43.7% | 68.0% | 69.5% |
| Denton Medical | 126 | 50.7 | 52.7% | 55.8% | 68.5% |
| Millgate | 117 | 36.2 | 46.8% | 78.3% | 67.7% |
| Guide Bridge | 89 | 49.0 | 30.2% | 55.4% | 60.5% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Fifteen of twenty-five tracked measures trail England's three-year change, led by asthma reviews
Over 2023 to 2025, 15 of 25 tracked measures trail England's change. The widest relative lags are annual asthma reviews, which fell 5.4% (England +4.4%), and dementia register prevalence, which fell 3.1% (England +6.0%, Tameside (LAD) +4.7%). Non-frail diabetes HbA1c control also fell 1.1% (England +4.4%). Strengths include learning disability QOF prevalence change of +21.5% (England +5.4%) alongside 367 patients on the register. For severe mental illness, 12-month blood pressure checks rose 8.4 pp (England +4.4 pp) to 88.5%, and alcohol recording rose 8.9 pp (England +5.4 pp) to 88.2%.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Asthma reviews
Dementia register
Diabetes HbA1c control
Depression register
Asthma register
Breast screening (53-70)
BP check (SMI)
Alcohol record (psychosis)
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Tameside (LAD) | Asset | PCN | Tameside (LAD) |
|---|---|---|---|---|---|
| Care homes (catchment) | 10 (313 beds) | n/a | Schools (catchment) | 54 | n/a |
| Children's centres | 6 | 16 | Places of worship | 29 | 104 |
| Libraries | 4 | 7 | Homelessness support (VCS) | 1 | 2 |
| Primary schools (LA maintained) | 6 | 22 | Primary academies | 15 | 46 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Structured asthma review and inhaler recall
Annual asthma reviews are 57.7% (Tameside (LAD) 62.2%; England 65.7%), falling 5.4% over 2023 to 2025 (England +4.4%), leaving a scale indicator of 1,468 unreviewed patients across the 3,469 register. For discussion: run structured asthma recall using a single template, offering after-school slots and reviewing repeat inhaler prescribing. Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
Under-80s hypertension titration and recall
Across 9,082 hypertension patients, under-80s blood pressure control is 60.3% (Tameside (LAD) 65.2%; ICB 68.6%; England 67.8%), falling 0.1% over 2023 to 2025 (England +3.2%), while overall treated to target is 64.7% (England 70.3%). Moderate effort to run.
Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.
Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).
Option 3
Dementia register coding and case-finding audit
Dementia prevalence is 0.7% (350 patients; Tameside (LAD) 0.8%; England 0.8%) and fell 3.1% over 2023 to 2025 (England +6.0%), giving an unadjusted benchmark gap range of +68 to +69 patients. For discussion: audit clinical records for uncoded memory clinic letters or cognitive assessments and review care-home case-finding routes. Low cost, quick to run.
Evidence base: dementia diagnosis rates lag in deprived and minority ethnic populations and in care homes; the register is the cohort for diagnosis-rate improvement and the annual dementia review, and diagnosis and post-diagnostic support delay care-home entry.
Policy anchor: national dementia diagnosis-rate ambition of 66.7%; 95% of people with complex needs to have an agreed care plan by 2027.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Older adult frailty coordination (p2) | Aged 65+ | Neighbourhood health framework · NHS vaccination strategy | PCN |
| Two-track Core20 resource allocation (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| Sustain SMI physical health checks (p4) | SMI register with a BP check in the last 12 months | MHIS · From Harm to Hope | PCN |
| Hypertension titration and recall review (p5) | Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Pre-school booster recall outreach (p6) | 4-in-1 pre-school booster (DTaP/IPV) coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Cervical screening uptake review (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Practice telephony and triage review (p9) | GPPS easy to contact the practice by phone | 10YHP, hospital to community | Practice |
| Option 1 · Structured asthma review and inhaler recall (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) · Asthma management items prescribed per 1000 5-19 Population | Core20PLUS5 respiratory | PCN |
| Option 2 · Under-80s hypertension titration and recall (p12) | Hypertension register · Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) · Hypertension patients treated to target | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Option 3 · Dementia register coding and case-finding audit (p12) | Dementia register · Dementia: QOF prevalence · Aged 65+ | 66.7% diagnosis ambition · 95% care plan 2027 | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | Local authority | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
